- Home
- BLRX vs XAIR Comparison
BLRX vs XAIR Comparison
Compare BLRX & XAIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BLRX | XAIR |
|---|---|---|
| Founded | 2003 | 2011 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.6M | 10.5M |
| IPO Year | 2011 | N/A |
Fundamental Metrics
Financial Performance| Metric | BLRX | XAIR |
|---|---|---|
| Price | $2.98 | $1.75 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $19.00 | $11.00 |
| AVG Volume (30 Days) | 23.3K | ★ 21.8M |
| Earning Date | 11-24-2025 | 02-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $12,735,000.00 | $5,802,000.00 |
| Revenue This Year | N/A | $127.85 |
| Revenue Next Year | N/A | $165.47 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 147.74 |
| 52 Week Low | $2.30 | $0.67 |
| 52 Week High | $7.77 | $10.40 |
Technical Indicators
Market Signals| Indicator | BLRX | XAIR |
|---|---|---|
| Relative Strength Index (RSI) | 42.91 | 62.87 |
| Support Level | $2.82 | $0.84 |
| Resistance Level | $2.99 | $2.66 |
| Average True Range (ATR) | 0.18 | 0.24 |
| MACD | 0.02 | 0.14 |
| Stochastic Oscillator | 46.66 | 52.69 |
Price Performance
Historical ComparisonAbout BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.
About XAIR Beyond Air Inc.
Beyond Air Inc is a commercial-stage medical device and biopharmaceutical company that develops a Nitric Oxide (NO) Generator and Delivery System that uses NO generated from ambient air and delivers precise amounts of NO to the lungs for the potential treatment of respiratory and other diseases. The firm is applying its therapeutic expertise to develop treatments for pulmonary hypertension, in addition to treatments for lower respiratory tract infections.